Low-dose acetylsalicylic acid for cancer prevention considering risk factors: a retrospective cohort study
Purpose Aspirin (acetylsalicylic acid) has been reported to protect against certain cancers. However, patient-related risk factors may moderate protective effects, including excess weight, smoking, risky alcohol use, and diabetes. We explore the cancer-risk relationship between aspirin intake and th...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10459.1/463602 |
| Acceso en línea: | https://doi.org/10.1016/j.annepidem.2023.06.002 https://hdl.handle.net/10459.1/463602 |
| Access Level: | acceso abierto |
| Palabra clave: | Aspirin Acetylsalicylic acid Risk factor Lifestyle Comorbidity Cancer Retrospective cohort study |
| Sumario: | Purpose Aspirin (acetylsalicylic acid) has been reported to protect against certain cancers. However, patient-related risk factors may moderate protective effects, including excess weight, smoking, risky alcohol use, and diabetes. We explore the cancer-risk relationship between aspirin intake and those four factors. Methods Retrospective cohort study of cancers, aspirin intake, and four risk factors in persons aged ≥50 years. Participants received medication during 2007–2016, and cancers were diagnosed in 2012–2016. Adjusted hazard ratios (aHR) for 95% confidence intervals (95%CI) were calculated for aspirin intake and risk factors using Cox proportional hazard modeling. Results Of 118,548 participants, 15,793 consumed aspirin, and 4003 had cancer. Results indicated a significant protective effect of aspirin against colorectal (aHR: 0.7; 95%CI: 0.6–0.8), pancreatic (aHR: 0.5; 95%CI: 0.2–0.9), prostate (aHR: 0.6; 95%CI: 0.5–0.7) cancers and lymphomas (aHR: 0.5; 95%CI: 0.2–0.9), and also, although not significantly, against esophageal (aHR: 0.5; 95%CI: 0.2–1.8), stomach (aHR: 0.7; 95%CI: 0.4–1.3), liver (aHR: 0.7; 95%CI: 0.3–1.5), breast (aHR: 0.8; 95%CI: 0.6–1.0), and lung and bronchial (aHR: 0.9; 95%CI: 0.7–1.2) cancers. Aspirin intake was not significantly protective against leukemia (aHR: 1.0; 95%CI: 0.7–1.4) or bladder cancer (aHR: 1.0; 95%CI: 0.8–1.3). Conclusions Our results suggest that aspirin intake is associated with a reduced incidence of colorectal, pancreatic, and prostate cancers and lymphomas. |
|---|